FFA
ZYNE

Freedman Financial Associates’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Freedman Financial Associates’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$1K – 464
2022
Q1 		$1K Hold
300
– – ﹤0.01% 482
2021
Q4 		$1K Hold
300
– – ﹤0.01% 450
2021
Q3 		$1K Hold
300
– – ﹤0.01% 469
2021
Q2 		$2K Sell
300
-600
-67% -$2.88K ﹤0.01% 446
2021
Q1 		$4K Hold
900
– – ﹤0.01% 410
2020
Q4 		$3K Buy
+900
New +$3.42K ﹤0.01% 426

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Freedman Financial Associates's ZYNE Position: Q2 2022 in Review

Freedman Financial Associates sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2022, closing a stake of 300 shares — an estimated $1K sold.

Freedman Financial Associates first reported a position in ZYNE in Q4 2020 and held it in 6 quarters. The position peaked at $4K in Q1 2021. 56 funds tracked by Wall St. Rank hold ZYNE as of Q2 2022.

  • Freedman Financial Associates reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 300 Zynerba Pharmaceuticals, Inc shares in Q2 2022, an estimated $1K.
  • Freedman Financial Associates first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Zynerba Pharmaceuticals, Inc position peaked at $4K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.